Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 6/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | SPNS2 | Q8IVW8 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179004 | 0.89 | AGER (0.42) | AGERHSD11B1TP53MAPTSMN1; SMN2 | |
| SCHEMBL4457149 | 0.86 | AGER (0.51) | AGERHSD11B1SPNS2TLR8GSK3B | |
| SCHEMBL6173167 | 0.83 | LMNA (0.39) | AGERDHODHMAPTSMN1; SMN2 | |
| SCHEMBL6178920 | 0.81 | GPR119 (0.41) | HSD11B1TP53MAPTSMN1; SMN2 | |
| SCHEMBL6175631 | 0.79 | PTGS1 (0.55) | HSD11B1MAPTSMN1; SMN2 | |
| SCHEMBL6175591 | 0.78 | MAPT (0.39) | HSD11B1MAPTSMN1; SMN2 | |
| SCHEMBL6178053 | 0.78 | AGER (0.43) | AGERSPNS2TLR8MAPTSMN1; SMN2 | |
| SCHEMBL6173956 | 0.78 | CXCR3 (0.40) | MAPTSMN1; SMN2 | |
| SCHEMBL6177260 | 0.77 | AGER (0.43) | AGERSPNS2TLR8TP53MAPT | |
| SCHEMBL6177327 | 0.76 | SPNS2 (0.43) | AGERHSD11B1SPNS2TLR8TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956050-B2 | Imidazole compounds as anti-inflammatory and analgesic agents | PFIZER, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1494667-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | Pfizer Japan Inc. (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | HIRANO MISATO (JP) | 2003-11-27 | — | — | US | disclosed |
| WO-2003086390-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, PTGES | AGER 4034/4885HSD11B1 88/4885SPNS2 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.